Pincus Capital Management LP Makes New $2.11 Million Investment in Zoetis Inc. $ZTS

Pincus Capital Management LP bought a new position in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, Holdings Channel reports. The institutional investor bought 16,765 shares of the company’s stock, valued at approximately $2,109,000. Zoetis comprises approximately 1.4% of Pincus Capital Management LP’s investment portfolio, making the stock its 17th biggest position.

Several other hedge funds have also added to or reduced their stakes in ZTS. Norges Bank bought a new stake in Zoetis in the fourth quarter worth $734,425,000. Vanguard Group Inc. boosted its holdings in Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. Diamond Hill Capital Management Inc. bought a new stake in Zoetis in the third quarter worth $394,010,000. Nordea Investment Management AB boosted its holdings in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. boosted its holdings in Zoetis by 256.7% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock worth $266,888,000 after acquiring an additional 1,560,314 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Buying and Selling at Zoetis

In other news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction on Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by company insiders.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Robbins Geller, Rosen, Kaplan Fox, Levi & Korsinsky, and others, issued class-action alerts related to Zoetis shareholders who purchased stock between January 14, 2025 and May 6, 2026, signaling rising litigation risk and possible financial exposure for the company. Article Title
• Negative Sentiment: The lawsuits allege Zoetis and some executives made misleading statements, including claims that generic safety and competition warnings failed to disclose specific known risks, which could hurt confidence in management and future disclosures. Article Title
• Neutral Sentiment: One market piece noted Zoetis as among the most oversold S&P 500 stocks so far in 2026, which may suggest the stock has already absorbed some negative expectations, but the item itself does not provide a fresh operational catalyst. Article Title

Zoetis Stock Down 0.1%

ZTS stock opened at $77.61 on Tuesday. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The business’s 50-day moving average is $103.52 and its two-hundred day moving average is $116.71. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a market cap of $32.54 billion, a price-to-earnings ratio of 12.87, a P/E/G ratio of 1.27 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the company posted $1.48 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.89 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio is currently 35.16%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several analyst reports. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Bank of America upped their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Stifel Nicolaus lowered their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. lowered their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.